Fast Five Quiz: Anticoagulation in Chronic Kidney Disease and Atrial Fibrillation

Sandeep K. Goyal, MD


March 08, 2022

A recent retrospective study assessing dosing strategies of DOACs in patients with moderate to severe renal impairment found that more than one quarter of patients received initial doses that were inappropriate on the basis of their renal function. These inappropriate doses were mostly due to underdosing.

Patients with renal impairment required DOAC dose adjustment, and overdosing of DOACs provide no efficacy benefit. Further, overdosing has been associated with worse safety and increased risk for bleeding. Underdosing has been associated with increased risk for stroke and worse safety as well.

Learn more about the management of AF in patients with ESKD.

Editor's Recommendations


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.